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Drug-resistant tuberculosis (TB) remains extremely difficult to treat because there are often
few remaining active medications and limited diagnostic options to detect resistance. Resis-
tance to isoniazid is typically caused by mutations in either katG or the inhA promoter. inhA
mutations confer low-level resistance to isoniazid and cross-resistance to ethionamide
while katGmutations confer high-level isoniazid resistance and no cross-resistance. Line
Probe Assays (LPAs) that detect mutations in katG and inhA are currently performed on all
positive TB cultures in KwaZulu-Natal province, South Africa, but the frequency of inhA
mutations in drug-resistant TB patients has not been examined.
Methods
We sought to determine the proportion of patients who could potentially benefit from high-
dose isoniazid and who may be resistant to ethionamide. We reviewed 994 LPA (Hain
MTBDRplus) results at the TB reference laboratory in KwaZulu-Natal to determine the fre-
quency of mutations in either katG or the inhA promoter. We stratified these results by drug-
resistance category (i.e., MDR-TB, pre-XDR-TB, and XDR-TB) as determined by pheno-
typic drug-susceptibility testing.
Results
Among MDR- and XDR-TB isolates, the prevalence of inhAmutations without a concurrent
katGmutation was 14.8% and 10.3% respectively. The prevalence of inhAmutations with
OR without a katGmutation was 30.3% and 82.8%, respectively.
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Conclusion
More than 10% of patients with MDR- and XDR-TB may benefit from high-dose isoniazid.
Although ethionamide is empirically included in all MDR- and XDR-TB regimens, nearly a
third of MDR-TB patients and a majority of XDR-TB patients likely have resistance to ethion-
amide. Laboratories performing line probe assays should report specific band patterns so
that clinicians may adjust treatment regimens accordingly.
Introduction
South Africa has one of the world’s worst epidemics of multidrug-resistant (MDR) and exten-
sively drug-resistant (XDR) tuberculosis (TB). The incidence of MDR-TB in South Africa has
increased 5-fold since 2002 and there were 26,000 cases reported in 2013 [1]. Management of
MDR- and XDR-TB is challenging, in part, because although treatment guidelines advise using
a minimum of 4 active medications [2], there are often few remaining active drugs to which the
patient’s isolate is susceptible.
Although one gene is responsible for ~95% of rifampin (RIF) resistance, resistance to isonia-
zid (INH) is generally due to mutations in one of two major genes: katG or the inhA promoter.
Mutations in katG typically result in high-level INH resistance but do not generate cross-
resistance with any other known TB medication [3]. In contrast, inhA promoter mutations
produce low-level resistance to INH and, additionally, confer high-level cross-resistance to eth-
ionamide, a second-line TB medication used in most MDR- and XDR-TB regimens [4–7]. The
issue of cross-resistance is critically important to patients with drug-resistant TB as treatment
often relies on the empiric use of second and third-line anti-TB drugs with poor efficacy and
tolerability. The availability of any additional active medications can significantly improve
treatment outcomes.
Use of fewer than 4 drugs or use of drugs to which the isolate is resistant risks treatment fail-
ure and generation of further resistance. If patients with MDR-TB are resistant to ethionamide
but treated with a regimen containing it, the combination may not be sufficient to prevent
emergent resistance to other medications in the regimen—possibly resulting in XDR-TB. In
South Africa, susceptibility testing to ethionamide is not routinely performed, but in patients
with MDR-TB, ethionamide is usually assumed to be active and included in all regimens
because most patients have never previously received the drug. Ethionamide, however, adds no
benefit to a patient with an inhA promoter mutation, and may, in fact, cause considerable tox-
icity, such as nausea and hypothyroidism. High-dose INH has been shown, in some studies, to
add considerable benefit to patients with MDR-TB and low-level INH resistance [8, 9]. Identi-
fication of those patients who might benefit from high-dose INH could dramatically improve
treatment outcomes for some patients with MDR- or XDR-TB. Patients with a katGmutation,
however, would not be expected to benefit from high-dose INH.
The practical utility of knowing which gene is mutated for a given patient depends on how
common inhAmutations are in a given setting. The province of KwaZulu-Natal was the site of
the first reported XDR-TB outbreak [10] and remains the epicenter of the drug-resistant TB
epidemic, with more than 6000 cases of MDR-TB reported in 2012 [11]. If a substantial pro-
portion of patients have isolates with an inhA promoter mutation, then a large number could
potentially benefit from high-dose INH if the providers know which patients have that muta-
tion. Availability of such information will also reduce ineffective use of ethionamide in these
patients.
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Line probe assays (LPAs) are rapid, genotypic tests ofMycobacterium tuberculosis (MTB)
resistance. LPAs use polymerase chain reaction to amplify specific resistance-determining
regions/genes fromMTB DNA present in the sputum sample or culture isolate. The assays
detect mutations in the most common resistance genes for INH and RIF (i.e., katG & inhA,
and rpoB respectively) and provide results in approximately 5 hours. In KwaZulu-Natal, LPAs
were added to the TB diagnostic algorithm in 2009 and all positive cultures are now routinely
tested with an LPA to screen for genotypic resistance to either INH or RIF.
To determine the proportion of patients who might 1) benefit from high-dose INH and/or
2) harbor resistance to ethionamide, we retrospectively reviewed the results of LPAs performed
at the TB reference laboratory for KwaZulu-Natal province and calculated the relative propor-
tions of patients with katG and/or inhA promoter mutations.
Methods
Setting
KwaZulu-Natal province has a population of 10.5 million and a TB incidence of 897 cases per
100,000 population [12]. There is a single TB reference laboratory for the province where all
mycobacterial cultures and drug-susceptibility testing are performed. LPAs (MTBDRplus,
Hain Lifesciences) are performed on all positive cultures to rapidly identify drug resistance,
and are performed in accordance with the manufacturer’s guidelines. All isolates with geno-
typic resistance to either INH or RIF undergo phenotypic agar proportion drug-susceptibility
testing (DST) to INH (1 mg/L), RIF (2 mg/L), streptomycin (2 mg/L), kanamycin (16 mg/L)
and ofloxacin (2 mg/L). Until recently, LPA results were sent to the treating clinician and
reported as either “resistant” or “susceptible” to either drug but the specific band pattern (i.e.,
mutation results) were recorded only at the laboratory. The lab performs approximately 13,000
liquid TB cultures and 2000 LPAs each month.
Data Collection
We reviewed 1000 routine LPA results performed at the laboratory from July 2012 to July
2013; we selected a group of consecutive results from each month of the year to account for
possible seasonal variation or a single cluster (mean 76±13 samples per month). Isolates
were eligible for inclusion if they showed resistance in any of the three genes tested by LPA.
We recorded the specific polymorphisms in each gene as well as the results of phenotypic
DST. Using the phenotypic DST as the gold standard, we categorized each isolate as
MDR-TB (resistance to only INH plus RIF), pre-XDR-TB (resistance to INH, RIF and either
ofloxacin or kanamycin, but not both), or XDR-TB (resistance to INH, RIF, ofloxacin and
kanamycin).
If multiple isolates were identified from the same patient, only the first isolate was included
and any isolates for which phenotypic DST results were not available were excluded.
Analysis
To determine how many subjects might have been eligible for high-dose INH, we calculated
the proportion of isolates containing an inhA promoter mutation but which did not have a
katG mutation, and stratified these results by drug-resistance category. Similarly, to deter-
mine the number of subjects who would not have benefitted from ethionamide, we calcu-
lated the proportion of isolates with an inhA mutation with or without a katG mutation.
Lastly, we examined the specific polymorphisms present in each gene to determine if any
inhA Promoter Mutations in M/XDR-TB
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single locus was more or less common than others or associated with a particular resistance
category.
Ethics Statement
The study was approved by the Ethics Committees of the University of KwaZulu-Natal and
Albert Einstein College of Medicine. These committees waived the requirement for informed
consent as all data were previously collected during the course of routine medical care and the
study did not pose any additional risks to the patients.
Results
Among the 1000 patient isolates with available LPA results examined, 6 were missing pheno-
typic DST results and were excluded. The remaining 994 isolates represented all 11 districts of
the province, drawing from 56 different hospitals and clinics.
Of the 994 isolates with phenotypic DST results, 70 (7.0%) had RIF mono-resistance and
were also excluded from further analysis. Of the remaining 924 isolates 129 (14.0%) had INH
mono-resistance, 694 (75.1%) were MDR-TB, 72 (7.8%) were pre-XDR-TB, and 29 (3.1%)
were XDR-TB (Table 1). Twenty-one (2.3%) and 91 (9.8%) of isolates were classified by LPA as
RIF mono-resistant and INHmono-resistant, respectively, though phenotypic DST showed
them to be MDR-, pre-XDR- or XDR-TB and thus resistant to both INH and RIF. In these iso-
lates, the LPA did not identify the resistance polymorphisms for INH and RIF respectively.
One isolate was incorrectly classified by LPA as RIF-resistant when the phenotypic DST
showed susceptibility and one isolate was incorrectly classified by LPA as INH-resistant when
DST showed susceptibility.
Overall, 132 (14.2%) isolates had an inhA promoter mutation without a concurrent katG
mutation, representing 14.8% of those with MDR-TB, 4.2% of those with pre-XDR-TB and
10.3% of those with XDR-TB (Fig 1). These patients could potentially benefit from the addition
of high-dose INH to their treatment regimen. Three hundred and six (33.1% of 924) isolates
had an inhAmutation with OR without a katGmutation, representing 30.3% of those with
MDR-TB, 47.2% of those with pre-XDR-TB, and 82.8% of those with XDR-TB (p<0.001 for
trend). These patients are likely resistant to ethionamide.
Table 1. Results of line probe assay testing by phenotypic drug susceptibility testing result.
LPA Results (mutation present)
INH Mono-resistance RIF Mono-
resistance


















21 89 15 1 1 2 0 129
RIF Mono-
resistance
0 1 0 68 1 0 0 70
MDR-TB 4 28 38 21 99 435 69 694
Pre-XDR-TB 0 3 6 0 3 35 25 72
XDR-TB 0 1 11 0 3 4 10 29
TOTAL 25 122 70 90 107 476 104 994
INH: isoniazid; RIF: rifampin; LPA: line probe assay; MDR: multidrug-resistant; XDR: extensively drug-resistant tuberculosis. TB: tuberculosis; DST: drug-
susceptibility test
doi:10.1371/journal.pone.0135003.t001
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Specific polymorphism data was available for 754 (75.9%) isolates. Among the 232 isolates
with an inhAmutation (regardless of katG), 165 (71%) had the -15C!T mutation and the
remaining 67 (29%) had the -8T!Amutation. No isolates carried either the -16A!G or the
-8T!C polymorphisms (Table 2).
Fig 1. Proportion of isolates with katG and/or inhA promoter mutations by drug resistance category.
doi:10.1371/journal.pone.0135003.g001
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Discussion
This is the first study to examine the prevalence of inhA promoter mutations among a large
population of patients with drug-resistant TB in KwaZulu-Natal. We examined results of rou-
tinely-performed LPAs over a one-year period from the single reference lab in the province
and found that more than 10% of patients with MDR-, pre-XDR-, and XDR-TB have inhA pro-
moter mutations without a concurrent katGmutation. These data underscore the need to clar-
ify the effectiveness of high-dose INH, as a large number of patients in KwaZulu-Natal could
potentially benefit if the efficacy of this therapy is confirmed. Indeed, some practitioners in
South Africa have already started using high-dose INH out of desperation for patients with
XDR-TB, but this is often in the absence of knowing the specific resistance mutations.
Several recent reports have examined relative frequencies of katG and inhA promoter muta-
tions in INH-resistant isolates and have shown considerable geographic variation, with 0.8%
frequency of inhA (without katG) mutation in Ethiopia [13], 4% in Poland [14], 9.6% in
Chonqing, China [15], and 22% in the Philippines [16]. In Saudi Arabia, a study of isolates
from 9 regional centers found that inhAmutations were more common in Southeast Asian
immigrants compared to both the autochthonous population as well as African immigrants
[17]. A study from the Western and Eastern Capes of South Africa found that nearly 40% of
MDR-TB isolates carried an inhA promoter mutation without concurrent katGmutation [18],
but there is considerable genetic diversity of TB throughout South Africa and this precludes
extrapolating results between provinces [19].
INH is a highly potent and rapid killer of MTB. The discovery that different genetic poly-
morphisms cause different levels of INH resistance could have important implications in the
management of MDR- and XDR-TB. If low-level resistance to INH can be overcome with
higher doses of INH, then this would add a much-needed effective drug to otherwise weak regi-
mens for MDR- or XDR-TB. To date, the evidence for using high-dose INH is promising, but
sparse. One randomized, three-arm, controlled trial in India compared high-dose INH, nor-
mal-dose INH or placebo plus an optimized background regimen for MDR-TB.[8] Patients
who received high-dose INH achieved culture conversion significantly faster than those in the
other two groups. There was no statistically significant difference in the overall proportion con-
verting by 6 months, but this was limited by the small sample sizes in each group. One recent
observational study found that a novel, short-course MDR-TB regimen containing high-dose
INH (along with a regimen containing gatifloxacin, kanamycin, clofazimine, prothionamide,
ethambutol and pyrazinamide) achieved excellent treatment outcomes with only 9 months of
therapy, but this study lacked a control arm [9].
In our study, we also found that a large number of patients had an inhA promoter mutation
with or without a concurrent katGmutation, signifying that these patients are likely resistant
Table 2. Specific inhA promoter mutations found in each drug-resistance category.
Mutation -15C/T -16A/G -8T/C -8T/A Total
DST Category
INH Mono-Resistance 19 (54%) 0 0 16 (46%) 35
MDR-TB 123 (75%) 0 0 40 (25%) 163
Pre-XDR-TB 21 (78%) 0 0 6 (22%) 27
XDR-TB 2 (29%) 0 0 5 (71%) 7
TOTAL 165 (71%) 0 0 67 (29%) 232
INH: isoniazid; DST: drug susceptibility testing; MDR: multidrug-resistant; XDR: extensively drug-resistant
doi:10.1371/journal.pone.0135003.t002
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to ethionamide. Because ethionamide is included in most MDR- and XDR-TB regimens,
patients with ethionamide resistance are unnecessarily subjected to its considerable toxicity.
The frequency of inhA promoter mutations increased as the overall drug-resistance of the
isolate increased, from MDR-TB to pre-XDR-TB to XDR-TB, but this could be due to
increased clonality from transmitted strains. We have previously shown that TB strain diversity
(as measured by spoligotyping) decreases with increasing drug-resistance in KwaZulu-Natal
[20].
This study has several limitations. This was a retrospective study of laboratory records of
routine testing. The original TB isolates were not available and we were thus unable to measure
minimum inhibitory concentrations for INH to precisely correlate the LPA genotypic results
with high or low-level phenotypic resistance. Similarly, we were unable to perform phenotypic
resistance testing to ethionamide to confirm cross-resistance in those with an inhA promoter
mutation. Since the original discovery of inhA, however, many groups have found an associa-
tion between low-level INH resistance and cross-resistance to ethionamide [5]. Secondly, we
did not sequence any of the other minor genes associated with INH-resistance (e.g., ahpC,
kasA, ndh, nat andmshA). While almost all isolates in our study had a katG or inhA promoter
mutation, it is possible that some of those with only an inhA promoter mutation had an addi-
tional, undetected mutation elsewhere, conferring high-level INH resistance and obviating the
potential benefit of high-dose INH. The Hain LPA, however, was specifically designed to cap-
ture only katG and inhA because mutations in these two genes represent the overwhelming
majority of INH resistance from diverse geographic areas.
KwaZulu-Natal is the largest province in South Africa and has the highest number of both
TB and drug-resistant TB cases in the country. Mortality for drug-resistant TB remains excep-
tionally high and while new drugs and diagnostic tests may help improve outcomes in the long
term, the National TB program, and programs around the world will need to optimize the use
of existing medications in the short term. Our data have immediate implications for changing
practice in KwaZulu-Natal, but also suggest that other countries with drug-resistant TB should
conduct similar surveys and adjust diagnostic and management strategies accordingly.
LPAs provide rapid and actionable information for health providers of patients with drug-
resistant TB. Given the high prevalence of inhA promoter mutations among patients with
drug-resistant TB in certain settings, providing specific gene mutations when reporting LPA
results may allow clinicians to adjust a patient’s regimen and maximize its effectiveness. To
that end, the reference laboratory in KwaZulu-Natal province recently began providing specific
gene mutations with LPA results. Further studies are required to determine the true effective-
ness of high-dose INH for patients with low-level INH resistance.
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